Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: Analyses from the Hypopituitary Control and Complications Study

European Journal of Endocrinology

Volumn 172, Issue 6, 2015, Pages 779-790

  Child, Christopher J ^a   Conroy, Daniel ^b   Zimmermann, Alan G ^a   Woodmansee, Whitney W ^c   Erfurth, Eva Marie ^d   Robison, Leslie L ^e  

^a ELI LILLY AND COMPANY   (United States)

^b SYNEOS HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CRANIOPHARYNGIOMA; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPHYSIS ADENOMA; INTRACRANIAL TUMOR; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OBSERVATIONAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE RISK; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STANDARDIZED INCIDENCE RATIO; ADENOMA; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DEFICIENCY; HYPOPITUITARISM; INCIDENCE; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROSTATIC NEOPLASMS;

ADENOMA; ADULT; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CRANIOPHARYNGIOMA; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 84930607776     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-1123     Document Type: Article

References (48)

1. Pekic S & Popovic V. GH therapy and cancer risk in hypopituitarism: What we know from human studies. European Journal of Endocrinology 2013 169 R89-R97. (doi:10.1530/EJE-13-0389).
2. Deodati A, Ferroli BB & Cianfarani S. Association between growth hormone therapy and mortality, cancer and cardiovascular risk: Systemic review and meta-analysis. Growth Hormone & IGF Research 2014 24 105-111. (doi:10.1016/j.ghir.2014.02.001).
3. Pollak MN, Schernhammer ES & Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews. Cancer 2004 4 505-518. (doi:10.1038/nrc1387).
4. Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska-Häggstöm M & Ranke MB. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). Journal of Clinical Endocrinology and Metabolism 2010 95 4449-4454. (doi:10.1210/jc. 2010-0287).
5. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM & Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004 363 1346-1353. (doi:10.1016/S0140-6736(04)16044-3).
6. Samani AA, Yakar S, LeRoith D & Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews 2007 28 20-47. (doi:10.1210/er.2006-0001).
7. Seccareccia E & Brodt P. The role of the insulin-like growth factor-I receptor in malignancy: An update. Growth Hormone & IGF Research 2012 22 193-199. (doi:10.1016/j.ghir.2012.09.003).
8. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998 279 563-566. (doi:10.1126/science.279.5350.563).
9. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH & Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute 1999 91 620-625. (doi:10.1093/jnci/91.7.620).
10. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK & Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet. Oncology 2010 11 530-542. (doi:10.1016/S1470-2045(10)70095-4).
11. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, Wass JA & Besser M. Acromegaly, colonic polyps and carcinoma. Clinical Endocrinology 1997 47 17-22. (doi:10.1046/j. 1365-2265.1997.1911029.x).
12. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: A retrospective cohort study, United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734. (doi:10.1210/jcem.83.8.5007).
13. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA & Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013 16 294-302. (doi:10.1007/s11102-012-0420-x).
14. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL & HypoCCS International Advisory Board. Assessment of primary cancers in GH-treated adult hypopituitary patients: An analysis from the Hypopituitary Control and Complications Study. European Journal of Endocrinology 2011 165 217-223. (doi:10.1530/EJE-11-0286).
15. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ et al. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. Journal of Clinical Endocrinology and Metabolism 2013 98 980-988. (doi:10.1210/jc.2012-2684).
16. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology 2003 148 (Suppl 2) S9-S14. (doi:10.1530/eje.0.148S009).
17. Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, Cox C, Kong F & Fradkin JE. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. Journal of Pediatrics 2004 144 430-436. (doi:10.1016/j.jpeds.2003.12.036).
18. Swerdlow AJ, Higgins CD, Adlard P & Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: A cohort study. Lancet 2002 360 273-277. (doi:10.1016/S0140-6736(02)09519-3).
19. Svensson J, Bengtsson BA, Rosén T, Odén A & Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312. (doi:10.1210/jc. 2003-031601).
20. van Bunderen CC, van Nieuwpoort IC, Arwert LI, Heymans MW, Franken AA, Koppeschaar HP, van der Lely AJ & Drent ML. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. Journal of Clinical Endocrinology and Metabolism 2011 96 3151-3159. (doi:10.1210/jc.2011-1215).
21. Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson Å, Cara J, Feldt-Rasmussen U, Koltowska-Häggström M, Monson JP, Saller B, Wilton P & Abs R. Overall and cause-specific mortality in GH-deficient adults on GH replacement. European Journal of Endocrinology 2012 166 1069-1077. (doi:10.1530/EJE-11-1028).
22. Burman P, Mattsson AF, Johannsson G, Höybye C, Holmer H, Dahlqvist P, Berinder K, Engström BE, Ekman D, Erfurth EM et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. Journal of Clinical Endocrinology and Metabolism 2013 98 1466-1475. (doi:10.1210/jc.2012-4059).
23. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clinical Endocrinology 1998 49 441-445. (doi:10.1046/j.1365-2265.1998.00536.x).
24. Stochholm K, Gravholt CH, Laursen T, Laurberg P, Andersen M, Kristensen LØ, Feldt-Rasmussen U, Christiansen JS, Frydenberg M & Green A. Mortality and GH deficiency: A nationwide study. European Journal of Endocrinology 2007 157 9-18. (doi:10.1530/EJE-07-0013).
25. Erfurth EM, Bülow B, Mikoczy Z & Hagmar L. Incidence of a second tumor in hypopituitary patients operated for pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2001 86 659-662. (doi:10.1210/jc.86.2.659).
26. Chung TT, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL, Grossman AB, Besser GM & Monson JP. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clinical Endocrinology 2005 63 274-279. (doi:10.1111/j.1365-2265.2005.02338.x).
27. Jostel A, Mukherjee A, Hulse PA & Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clinical Endocrinology 2005 62 698-705. (doi:10.1111/j.1365-2265.2005.02282.x).
28. Karavitaki N, Warner JT, Marland A, Shine B, Ryan F, Arnold J, Turner HE & Wass JA. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clinical Endocrinology 2006 64 556-560. (doi:10.1111/j.1365-2265.2006.02508.x).
29. Murray RD, Darzy KH, Gleeson HK & Shalet SM. GH-deficient survivors of childhood cancer: GH replacement during adult life. Journal of Clinical Endocrinology and Metabolism 2002 87 129-135. (doi:10.1210/jcem.87.1.8146).
30. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WD, Brada M, Hayward RD, Brook CG et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. Journal of Clinical Endocrinology and Metabolism 2000 85 4444-4449. (doi:10.1210/jcem.85.12.7044).
31. Wilton P, Mattsson AF & Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). Journal of Pediatrics 2010 157 265-270. (doi:10.1016/j.jpeds.2010. 02.028).
32. SklarCA, Mertens AC, Mitby P, OcchiogrossoG, Qin J, Heller G, Yasui Y& Robison LL. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: A report fromthe Childhood Cancer Survivor Study. Journal of Clinical Endocrinology and Metabolism 2002 87 3136-3141. (doi:10.1210/jcem.87.7.8606).
33. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL & Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. Journal of Clinical Endocrinology and Metabolism 2006 91 3494-3498. (doi:10.1210/jc.2006-0656).
34. Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, Erfurth EM, Beck-Peccoz P, Blum WF, Robison LL & GeNeSIS and HypoCCS International Advisory Boards . Incidence of second neoplasm in childhood cancer survivors treated with GH: An analysis of GeNeSIS and HypoCCS. European Journal of Endocrinology 2013 168 565-573. (doi:10.1530/EJE-12-0967).
35. Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, Armstrong GT, Meadows A, Stovall M, Robison LL et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: A report from the Childhood Cancer Survivor Study. Journal of Clinical Endocrinology and Metabolism 2014 99 2030-2037. (doi:10.1210/jc.2013-4159).
36. Webb SM, Strasburger CJ, Mo D, Hartman ML, Melmed S, Jung H, Blum WF, Attanasio AF & HypoCCS International Advisory Board. Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. Journal of Clinical Endocrinology and Metabolism 2009 94 392-399. (doi:10.1210/jc.2008-0713).
37. Howlader N, Noone AM, KrapchoM, Garshell J, Neyman N, Altekruse SF, Kosary CL, YuM, Ruhl J, Tatalovich Z et al. (Eds). SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute. Based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Accessed on 23 July 2013 at: http://seer.cancer.gov/csr/1975-2010/.
38. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM & GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010. Accessed on 23 July 2013 at: http://globocan.iarc.fr.
39. Breslow NE & Day NE (Eds). Statistical Methods in Cancer Research. Volume II, - The Design and Analysis of Cohort Studies, vol 82, pp 65-69. IARC Scientific Publications: Lyon, France, 1987.
40. Perkins SM, Tu W, Underhill MG, Zhou XH & Murray MD. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety 2000 9 93-101. (doi:10.1002/(SICI)1099-1557(200003/04)9:2!93::AID-PDS474O3.0.CO;2-I).
41. Rosenbaum PR & Rubin DB. Reducing bias in observational studies using subclassification on propensity score. Journal of the American Statistical Association 1984 79 516-524. (doi:10.1080/01621459.1984. 10478078).
42. Shimatsu A, Tai S, Imori M, Ihara K, Taketsuna M, Funai J, Tanaka T, Teramoto A, Irie M& Chihara K. Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: A post-marketing observational study. Endocrine Journal 2013 60 1131-1144. (doi:10.1507/endocrj.EJ13-0083).
43. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC & Rose NR. Autoimmune hypophysitis. Endocrine Reviews 2005 26 599-614. (doi:10.1210/er.2004-0011).
44. Inskip PD, Ries LAG, Cohen RJ, Curtis RE. New malignancies following childhood cancer. In New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000, pp 465-482. eds RE Curtis, DM Freedman, E Ron, LAG Ries, DG Hacker, BK Edwards, MA Tucker & JF Fraumeni Jr. Bethesda, MD: National Cancer Institute, NIH Publ. No., 05-5302, 2006.
45. Jenkins PJ, Mukherjee A & Shalet SM. Does growth hormone cause cancer? Clinical Endocrinology 2006 64 115-121. (doi:10.1111/j.1365- 2265.2005.02404.x).
46. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL & Does GH. Does GH, replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? European Journal of Endocrinology 2002 146 807-811. (doi:10.1530/eje.0.1460807).
47. Buchfelder M, Kann PH, Wüster C, Tuschy U, Saller B, Brabant G, Kleindienst A, Nomikos P & German KIMS Board. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: A case control study. European Journal of Endocrinology 2007 157 149-156. (doi:10.1530/EJE-07-0164).
48. Olsson DS, Buchfelder M, Wiendieck K, Kremenevskaja N, Bengtsson BÅ, Jakobsson KE, Jarfelt M, Johannsson G & Nilsson AG. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. European Journal of Endocrinology 2012 166 1061-1068. (doi:10.1530/EJE-12-0077).